ADC Biotech Tubulis Closes Upsized $138M Financing Round 3/14/2024

Recently Laid Off? Contract Work Could Be an Attractive Option 3/14/2024

Vertex Fails to Convince UK Watchdog of CRISPR Therapy Casgevy’s Value 3/14/2024

Mirum Secures Livmarli’s Expansion into Familial Intrahepatic Cholestasis 3/14/2024

Merck to Start Trials of New HPV Vaccine and Single-Dose Gardasil Shot 3/14/2024

Career Coach: How to Truly Tailor a Resume 3/14/2024

PhRMA Loses Another Legal Battle as Court Sides with Arkansas Over Drug Discount Program 3/14/2024

The Unintended Consequences of Small Molecules 3/14/2024

Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for the company's 20-valent pneumococcal conjugate vaccine, marketed in the European Union under the brand name PREVENAR 20®, for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age.

There are thousands of diseases worldwide with no cure or available treatments. Traditional drug discovery and development takes decades and billions of dollars and more than 90% of these drugs fail in clinical trials. The emergence of artificial intelligence (AI) holds promise for streamlining and improving the entire process. However, ushering in a new era of AI-driven drug discovery requires costly and lengthy validation in preclinical cell, tissue, and animal models and human clinical trials.

A new study has shed light on the importance of the protein STAP-1 in activating certain immune cells. Understanding the role of STAP-1 in these cells could give researchers a better glimpse into immune-related disorders and ways to treat them.

The researchers found that STAP-1 plays an important role in the activation of T cells, which are white blood cells that play a critical role in defending the body against infections and maintaining overall health.

A team of University of Michigan researchers has successfully modified a naturally occurring chemical compound in the lab, resulting in advanced lead compounds with anti-HIV activity.

Their results, published March 7 in the Journal of Medicinal Chemistry, offer a new path forward in the development of drugs that could potentially help cure - rather than treat - HIV.

In a study published in Cell on March 5, Prof. ZHANG Xiaoming at the Shanghai Institute of Immunity and Infection (SIII) of the Chinese Academy of Sciences and Profs. GAO Qiang, FAN Jia and YANG Li at Fudan University have uncovered an unexpected level of complexity hidden within neutrophils, which were previously thought to be a relatively uniform population of short-lived immune cells.

Scientists discover a new way to disarm a deadly protein that also appears in cancers of the lung, breast and colon.

UC San Francisco researchers have designed a candidate drug that could help make pancreatic cancer, which is almost always fatal, a treatable, perhaps even curable, condition.

The new molecule permanently modifies a wily cancer-causing mutation, called K-Ras G12D, that is responsible for nearly half of all pancreatic cancer cases and appears in some forms of lung, breast and colon cancer.

New Cleveland Clinic-led research points to sildenafil (Viagra) as a potential treatment for Alzheimer's disease. The study provides evidence from computational models, insurance claims data and observations from brain cells in Alzheimer's patients.

Sildenafil is the main component of drugs used to treat erectile dysfunction (Viagra) and pulmonary arterial hypertension (Revatio).

Amgen Pushes Obesity Drug MariTide Forward, Reports 22% Q1 Revenue Growth 5/3/2024

Boehringer, Walgreens Team Up for Obesity Trial as Weight-Loss Drug Race Heats Up 5/3/2024

FDA’s Accelerated Approval of Sarepta DMD Gene Therapy Comes Under Fire 5/3/2024

BioSpace Heads to #ASGCT, Along with Thousands in Cell and Gene Therapy 5/3/2024

Novo Nordisk’s Wegovy Pricing Drops as Competition Heats Up with Eli Lilly 5/3/2024